A simplified cardiac risk score can identify plaque buildup and silent brain infarctions that could predict a serious stroke, acting as a red flag for patients without a history of CVD or other vascular problems.

CVS Pharmacy announced Sept. 28 it would be suspending the sales of all Zantac-brand and CVS Health-brand ranitidine products until further notice, pending the results of an FDA investigation.

Tests commissioned by NBC News have revealed that vitamin E—the suspected culprit behind some 800-plus reported cases of vaping-related lung illness—is present in many THC cartridges sold on the black market, alongside other toxicities like pesticides and myclobutanil.

An analysis of the long-running Framingham Heart Study has revealed that exposure to secondhand smoke in childhood increases a person’s lifetime risk of atrial fibrillation.

A therapeutic shoe designed to improve stroke survivors’ gait and symmetry was successful in a small-scale trial of six patients, according to a study published in the Journal of NeuroEngineering and Rehabilitation.

Drugmaker Novartis is halting the distribution of generic Zantac, or ranitidine, while the drug is investigated for NDMA, a probable human carcinogen.

The opioid crisis is to blame for an “alarming” number of cases of infective endocarditis, according to the American Heart Association.

A study published in the Annals of Internal Medicine Sept. 17 suggests daily aspirin could result in a net benefit for some people without established CVD, further muddying the debate over whether aspirin is an effective preventive tool for those without heart disease.